Vaccine strategies for human papillomavirus-associated cancers.
OBJECTIVE
To review novel immunologic strategies for the prevention and treatment of human papillomavirus infection and associated diseases. Both animal model systems and human protocols are discussed.


RESULTS
Many vaccine platforms for both prevention of human papillomavirus infection and treatment of associated disease have been developed. Virus-like particle constructs containing human papillomavirus capsid proteins have been shown to protect against human papillomavirus infection. Novel peptide or protein constructs containing modified E6 or E7 proteins, novel adjuvants, fusion proteins such as immunoglobulin-G-heavy chain E7, or heat shock proteins have been made as therapeutic modalities. In addition, many new recombinant vaccine vectors such as vaccinia, Listeria species, adenovirus, Semliki Forest vectors, and others have been developed as carriers of immunotherapeutic agents. Recently, chimeric virus-like particle vaccines have been developed to treat existing human papillomavirus-induced neoplasms.


CONCLUSIONS
Immunotherapy protocols using a variety of recombinant vectors and modified human papillomavirus proteins induce in-vitro T cell responses and may lead to tumor regression. Vaccine-induced in-vitro immune reactivity and clinical vaccine effects are often not well associated. Further analysis of ongoing human immunotherapy trials is awaited.
Kadish
Anna S
AS
Departments of Pathology, Obstetrics and Gynecology & Women's Health, Albert Einstein College of Medicine, 1695 Eastchester Road, Suite 601, Bronx, NY 10461, USA. kadish@aecom.yu.edu
Einstein
Mark H
MH
D000818:Animals; D001428:Bacterial Vaccines / Q000145:classification / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000145:classification / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015316:Genetic Therapy; D006801:Humans; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000188:drug therapy / Q000821:virology; D027383:Papillomaviridae; D030361:Papillomavirus Infections / Q000150:complications* / Q000628:therapy*; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA / Q000627:therapeutic use; D014765:Viral Vaccines / Q000145:classification / Q000627:therapeutic use*
D001428:Bacterial Vaccines; D019496:Cancer Vaccines; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; D014765:Viral Vaccines